Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cell Reports. Medicine|November 19, 2025
Voices: Future directions in targeting the tumor microenvironmentTanja de Gruijl, Catherine Sautès-Fridman, Daniela S Thommen, et al.
The Journal of Investigative Dermatology|June 18, 2015
In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic CellsMartine A Boks, Sven C M Bruijns, Martino Ambrosini, et al.
Cancer Metastasis Reviews|February 21, 2025
Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysisAiarpi Ezdoglian, Michel Tsang-A-Sjoe, Fatemeh Khodadust, et al.
Oncoimmunology|November 3, 2018
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapySadia Zafar, Suvi Sorsa, Mikko Siurala, et al.
Nature Medicine|March 6, 2007
Langerin is a natural barrier to HIV-1 transmission by Langerhans cellsLot de Witte, Alexey Nabatov, Marjorie Pion, et al.
Oncoimmunology|March 28, 2017
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapySadia Zafar, Suvi Parviainen, Mikko Siurala, et al.
Journal for Immunotherapy of Cancer|January 16, 2020
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivityJoão Manuel Santos, Camilla Heiniö, Victor Cervera-Carrascon, et al.
Biomaterials|December 4, 2014
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responsesRodney A Rosalia, Luis J Cruz, Suzanne van Duikeren, et al.
Oncoimmunology|June 5, 2013
Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapyWillemijn van den Ancker, Jurjen M Ruben, Theresia M Westers, et al.
Journal for Immunotherapy of Cancer|March 26, 2025
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trialBart Geboers, Florentine Timmer, Danielle Vos, et al.
Pageof 2